https://www.yiliao.com/index.php?action=history&feed=atom&title=MAP2K1
MAP2K1 - 版本历史
2026-04-28T21:53:30Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=MAP2K1&diff=311649&oldid=prev
2025年12月29日 (一) 15:50 77921020
2025-12-29T15:50:38Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2025年12月29日 (一) 15:50的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l7" >第7行：</td>
<td colspan="2" class="diff-lineno">第7行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: <del class="diffchange diffchange-inline">350px</del>; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: <ins class="diffchange diffchange-inline">360px</ins>; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"></div></td></tr>
<!-- diff cache key yixue20260209:diff::1.12:old-311648:rev-311649 -->
</table>
77921020
https://www.yiliao.com/index.php?title=MAP2K1&diff=311648&oldid=prev
2025年12月29日 (一) 15:50 77921020
2025-12-29T15:50:12Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2025年12月29日 (一) 15:50的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l7" >第7行：</td>
<td colspan="2" class="diff-lineno">第7行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'>−</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div> <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: <del class="diffchange diffchange-inline">340px</del>; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"></div></td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div> <div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: <ins class="diffchange diffchange-inline">350px</ins>; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"></div></td></tr>
<!-- diff cache key yixue20260209:diff::1.12:old-311647:rev-311648 -->
</table>
77921020
https://www.yiliao.com/index.php?title=MAP2K1&diff=311647&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2025-12-29T15:49:50Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>MAP2K1</strong>（Mitogen-Activated Protein Kinase Kinase 1），在生物学和临床上更为人熟知的名称是 <strong>MEK1</strong>。该基因编码一种具有<strong>双重特异性</strong>（Dual-Specificity）的蛋白激酶，它是经典的 <strong>RAS-RAF-MEK-ERK</strong> 信号级联通路中的核心“守门人”。MEK1 位于 RAF 激酶之下、ERK 激酶之上，负责将上游的促有丝分裂信号精确传递给效应分子 ERK，从而调控细胞的增殖、存活和分化。在肿瘤学中，MAP2K1 的体细胞突变或其上游（BRAF/RAS）的异常激活是<strong>[[黑色素瘤]]</strong>、<strong>[[非小细胞肺癌]]</strong>和<strong>[[朗格汉斯细胞组织细胞增生症]] (LCH)</strong> 的关键驱动因素；而其生殖系突变则会导致一种被称为<strong>[[心面皮肤综合征]]</strong> (CFC) 的发育障碍。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 340px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">MAP2K1 (MEK1) · 基因档案</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Gene & Protein Profile (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<br />
[[文件:MAPK_Pathway_MEK1.png|100px|RAS-RAF-MEK-ERK 信号级联]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">MAPK通路核心激酶</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc; width: 40%;">基因符号</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;"><strong>MAP2K1</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">常用别名</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">MEK1, MKK1, MAPKK1</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">编码蛋白</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">Dual specificity mitogen-activated protein kinase kinase 1</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">染色体位置</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">15q22.31</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">Entrez ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">5604</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">HGNC ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">6840</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">UniProt</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #1e40af;">Q02750</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #475569; background-color: #f8fafc;">分子量</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #f1f5f9; color: #0f172a;">~43-45 kDa</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; color: #475569; background-color: #f8fafc;">药物靶点</th><br />
<td style="padding: 8px 12px; color: #0f172a;">MEK Inhibitors (Trametinib等)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：双重特异性的信号阀门</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
MEK1 在信号传导中具有极高的底物特异性，它是唯一能激活 ERK 的激酶，也是 RAF 的主要底物，这种严谨的层级结构确保了信号传递的准确性。<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>双重特异性激酶 (Dual-Specificity Kinase)：</strong> MEK1 具有罕见的能力，能同时磷酸化下游底物 ERK1/2 活化环上的<strong>酪氨酸 (Tyr)</strong> 和 <strong>苏氨酸 (Thr)</strong> 残基（TxY 基序）。只有这两个位点都被磷酸化，ERK 才能被激活并入核。</li><br />
<li style="margin-bottom: 12px;"><strong>变构激活：</strong> 上游的 RAF 激酶通过磷酸化 MEK1 的丝氨酸位点（Ser218/Ser222）将其激活。许多致病性突变（如 K57N, Q56P）会破坏其自身抑制性螺旋结构，导致 MEK1 在没有 RAF 信号的情况下处于持续开放的活性构象。</li><br />
<li style="margin-bottom: 12px;"><strong>负反馈调节：</strong> 正常情况下，活化的 ERK 会反过来磷酸化 MEK1 和 RAF，抑制信号通路，防止过度激活。在肿瘤中，这种反馈机制常因突变而失效。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床景观：RASopathies 与耐药机制</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
MAP2K1 突变虽然总体频率低于 BRAF 或 KRAS，但在特定肿瘤亚型和耐药复发中扮演关键角色。<br />
</p><br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 90%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">疾病类型</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">变异形式</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">临床特征与意义</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">黑色素瘤 (Melanoma)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">体细胞突变 (6-8%)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">常见于 BRAF/NRAS 野生型的肿瘤中，或者作为 BRAF 抑制剂治疗后的<strong>继发性耐药机制</strong>出现。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">朗格汉斯细胞组织细胞增生症 (LCH)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">体细胞突变 (~20%)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">在 BRAF V600E 阴性的 LCH 病例中，MAP2K1 突变是最常见的驱动事件，且通常对 MEK 抑制剂高度敏感。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">非小细胞肺癌 (NSCLC)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">体细胞突变 (1%)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">罕见驱动基因。与吸烟状态关系较小，目前已有 MEK 抑制剂在该亚组中显示出抗肿瘤活性。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">心面皮肤综合征 (CFC Syndrome)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">生殖系突变</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">RASopathy 之一。表现为颅面部畸形、心脏缺损（肺动脉瓣狭窄）、皮肤异常和发育迟缓。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略：双药联合的金标准</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
MEK 抑制剂（MEKi）的开发是靶向治疗的重大胜利，特别是其与 BRAF 抑制剂的“黄金搭档”。<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>MEK 抑制剂：</strong><br />
<br>代表药物：<strong>[[Trametinib]]</strong> (曲美替尼), <strong>[[Cobimetinib]]</strong> (考比替尼), <strong>[[Binimetinib]]</strong> (比尼替尼), <strong>[[Selumetinib]]</strong> (司美替尼)。<br />
<br><span style="font-size: 0.9em; color: #64748b;">*特点：均为非ATP竞争性的别构抑制剂，这赋予了它们极高的选择性。Trametinib 具有最长的半衰期。Selumetinib 已获批用于治疗 1型神经纤维瘤病 (NF1) 相关的丛状神经纤维瘤。</span><br />
</li><br />
<li style="margin-bottom: 12px;"><strong>BRAF + MEK 联合阻断：</strong><br />
<br>单用 BRAF 抑制剂常导致反常的 MAPK 通路激活（Paradoxical Activation）并引发皮肤鳞癌。联合使用 MEK 抑制剂（如 Dabrafenib + Trametinib）不仅能<strong>延缓耐药性</strong>，还能通过阻断下游 ERK 激活来<strong>减轻毒副作用</strong>，已成为 BRAF V600E 突变黑色素瘤和肺癌的标准一线疗法。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键关联概念</h2><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>BRAF V600E：</strong> MEK1 最重要的上游激活信号，联合治疗的核心靶点。</li><br />
<li style="margin-bottom: 12px;"><strong>RASopathies：</strong> 由 RAS/MAPK 通路生殖系突变引起的一组发育综合征，包括 CFC 和 Noonan。</li><br />
<li style="margin-bottom: 12px;"><strong>别构抑制 (Allosteric Inhibition)：</strong> MEK 抑制剂的作用机制，不与 ATP 竞争，而是改变酶的构象。</li><br />
<li style="margin-bottom: 12px;"><strong>ERK1/2：</strong> MEK1 的唯一生理底物，通路效应的执行者。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Crews CM, Alessandrini A, Erikson RL. (1992).</strong> <em>The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product.</em> <strong>Science</strong>. <br><br />
<span style="color: #475569;">[学术点评]：发现性文献。首次克隆并测序了 MEK 基因，确立了其连接 Raf 与 ERK 的桥梁作用，完成了 MAPK 级联通路的拼图。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Rodriguez-Viciana P, et al. (2006).</strong> <em>Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.</em> <strong>Science</strong>. <br><br />
<span style="color: #475569;">[学术点评]：临床遗传学突破。发现 BRAF 和 MEK1/2 的生殖系突变是 CFC 综合征的病因，将发育生物学与肿瘤信号通路紧密联系起来。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Flaherty KT, et al. (2012).</strong> <em>Improved survival with MEK inhibition in BRAF-mutated melanoma.</em> <strong>New England Journal of Medicine (NEJM)</strong>. <br><br />
<span style="color: #475569;">[学术点评]：METRIC 研究。证实了 Trametinib 单药治疗 BRAF 突变黑色素瘤的生存获益，是首个获批的 MEK 抑制剂里程碑试验。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[4] <strong>Long GV, et al. (2014).</strong> <em>Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.</em> <strong>The Lancet</strong>. <br><br />
<span style="color: #475569;">[学术点评]：COMBI-d 研究。确立了“D+T”联合疗法优于单药疗法的地位，不仅疗效更好，而且显著降低了皮肤鳞癌等副作用的发生率。</span><br />
</p><br />
<br />
<p style="margin: 12px 0;"><br />
[5] <strong>Emery CM, et al. (2009).</strong> <em>MEK1 mutations confer resistance to MEK and B-RAF inhibition.</em> <strong>PNAS</strong>. <br><br />
<span style="color: #475569;">[学术点评]：耐药机制研究。揭示了 MEK1 突变是导致 BRAF 抑制剂继发性耐药的重要原因，强调了通路下游突变的临床意义。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1.5px solid #0f172a; border-radius: 8px; overflow: hidden; font-size: 0.95em;"><br />
<div style="background-color: #0f172a; color: #ffffff; text-align: center; font-weight: bold; padding: 10px; letter-spacing: 1px;">MAP2K1 · 知识图谱关联</div><br />
<div style="padding: 15px; background: #ffffff; line-height: 2.2; text-align: center; text-decoration: none;"><br />
[[黑色素瘤]] • [[Trametinib]] • [[BRAF V600E]] • [[ERK通路]] • [[心面皮肤综合征]] • [[LCH]] • [[非小细胞肺癌]] • [[别构抑制剂]]<br />
</div><br />
</div><br />
<br />
</div></div>
77921020